[go: up one dir, main page]

PL3463351T3 - Leczenie choroby parkinsona - Google Patents

Leczenie choroby parkinsona

Info

Publication number
PL3463351T3
PL3463351T3 PL17743097T PL17743097T PL3463351T3 PL 3463351 T3 PL3463351 T3 PL 3463351T3 PL 17743097 T PL17743097 T PL 17743097T PL 17743097 T PL17743097 T PL 17743097T PL 3463351 T3 PL3463351 T3 PL 3463351T3
Authority
PL
Poland
Prior art keywords
parkinson
disease
treatment
Prior art date
Application number
PL17743097T
Other languages
English (en)
Inventor
Nitin Krishnaji Damle
Sanjay Nandlalji MANDHANE
Manoj Atmaramji UPADHYA
Sameer Vishwanath MEHETRE
Gajanan Uttamrao CHIDREWAR
Prabal Sengupta
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Research Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Company Limited filed Critical Sun Pharma Advanced Research Company Limited
Publication of PL3463351T3 publication Critical patent/PL3463351T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL17743097T 2016-06-02 2017-06-02 Leczenie choroby parkinsona PL3463351T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201621019087 2016-06-02
IN201621019185 2016-06-02
PCT/IN2017/050224 WO2017208267A1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease
EP17743097.2A EP3463351B1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease

Publications (1)

Publication Number Publication Date
PL3463351T3 true PL3463351T3 (pl) 2022-06-20

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17743097T PL3463351T3 (pl) 2016-06-02 2017-06-02 Leczenie choroby parkinsona

Country Status (26)

Country Link
US (4) US10849887B2 (pl)
EP (2) EP3463351B1 (pl)
JP (1) JP6974357B2 (pl)
KR (1) KR102508288B1 (pl)
CN (1) CN109475539B (pl)
AU (1) AU2017273415B2 (pl)
CA (1) CA3024976A1 (pl)
CL (1) CL2018003431A1 (pl)
CY (1) CY1125285T1 (pl)
DK (1) DK3463351T3 (pl)
ES (1) ES2914782T3 (pl)
HR (1) HRP20220683T1 (pl)
HU (1) HUE059387T2 (pl)
IL (1) IL263188B (pl)
LT (1) LT3463351T (pl)
MX (1) MX385276B (pl)
MY (1) MY193754A (pl)
PH (1) PH12018502457B1 (pl)
PL (1) PL3463351T3 (pl)
PT (1) PT3463351T (pl)
RS (1) RS63243B1 (pl)
SG (1) SG11201810294QA (pl)
SI (1) SI3463351T1 (pl)
SM (1) SMT202200228T1 (pl)
UA (1) UA123018C2 (pl)
WO (1) WO2017208267A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2911040C (en) 2012-05-02 2021-11-16 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
CA3024976A1 (en) * 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
US12246009B2 (en) 2018-11-20 2025-03-11 Georgetown University Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
WO2020250133A1 (en) * 2019-06-11 2020-12-17 Sun Pharma Advanced Research Company Ltd. Treatment for synucleinopathies
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
AU2021317186A1 (en) 2020-07-31 2023-03-16 Sun Pharma Advanced Research Company Limited N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of Alzheimer's Disease
EP4518860A1 (en) 2022-05-02 2025-03-12 Sun Pharma Advanced Research Company Ltd Vodobatinib for reducing progression of parkinson's disease
KR20250040552A (ko) 2023-09-14 2025-03-24 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024194B8 (ru) * 2011-01-21 2016-11-30 Сан Фарма Адвансед Ресьорч Компани Лтд Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
CA2911040C (en) 2012-05-02 2021-11-16 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
US10150733B2 (en) * 2015-05-18 2018-12-11 Sun Pharma Advanced Research Company Ltd. Amidoheteroaryl aroyl hydrazide ethynes
CA3024976A1 (en) * 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease

Also Published As

Publication number Publication date
JP2019520344A (ja) 2019-07-18
SI3463351T1 (sl) 2022-07-29
RS63243B1 (sr) 2022-06-30
PH12018502457A1 (en) 2019-10-21
EP3463351A1 (en) 2019-04-10
US20210015805A1 (en) 2021-01-21
UA123018C2 (uk) 2021-02-03
MX385276B (es) 2025-03-18
IL263188B (en) 2021-08-31
DK3463351T3 (da) 2022-06-07
KR102508288B1 (ko) 2023-03-09
US20220273632A1 (en) 2022-09-01
LT3463351T (lt) 2022-06-10
HRP20220683T1 (hr) 2022-07-08
HUE059387T2 (hu) 2022-11-28
PH12018502457B1 (en) 2022-01-12
CN109475539A (zh) 2019-03-15
SMT202200228T1 (it) 2022-07-21
CA3024976A1 (en) 2017-12-07
CY1125285T1 (el) 2025-03-28
WO2017208267A1 (en) 2017-12-07
US11813252B2 (en) 2023-11-14
KR20190015257A (ko) 2019-02-13
EP3463351B1 (en) 2022-04-27
SG11201810294QA (en) 2018-12-28
MY193754A (en) 2022-10-27
BR112018074439A2 (pt) 2019-03-06
US10849887B2 (en) 2020-12-01
AU2017273415B2 (en) 2023-01-19
US20190275017A1 (en) 2019-09-12
JP6974357B2 (ja) 2021-12-01
CN109475539B (zh) 2021-12-28
CL2018003431A1 (es) 2019-05-10
ES2914782T3 (es) 2022-06-16
MX2018014944A (es) 2019-03-07
US20240066014A1 (en) 2024-02-29
US11583522B2 (en) 2023-02-21
IL263188A (en) 2018-12-31
PT3463351T (pt) 2022-06-02
AU2017273415A1 (en) 2018-12-06
EP4085912A1 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
IL280530A (en) Decarboxylase aromatic amino acid-encoding phylonucleotides for the treatment of Parkinson's disease
SG11201912154XA (en) Aadc polynucleotides for the treatment of parkinson's disease
IL285722A (en) Methods for treating Alzheimer's disease
IL263188B (en) Treatment for Parkinson's disease
IL247085A0 (en) Methods for treating Alzheimer's disease
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
EP3268086A4 (en) Lsd for the treatment of alzheimer's disease
IL246999A0 (en) Methods for treating Alzheimer's disease
IL263433A (en) Methods for treating Alzheimer's disease
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
ZA201807944B (en) Treatment for parkinson's disease
EP3244897A4 (en) Methods for treating alzheimer's disease
GB201518052D0 (en) Parkinson's disease treatment
HK40014282A (en) Methods for treating parkinson's disease
GB201504144D0 (en) Treatment of Parkinson's disease
GB201610205D0 (en) Therapies for parkinson's disease
GB201614863D0 (en) Alzheimer's disease
GB201511453D0 (en) Treatment of alzheimer's disease
GB201414038D0 (en) Alzheimer's disease